BLCO logo

BLCO
Bausch + Lomb Corp.

524
Mkt Cap
$5.82B
Volume
711,955.00
52W High
$18.92
52W Low
$10.83
PE Ratio
-26.40
BLCO Fundamentals
Price
$16.31
Prev Close
$15.90
Open
$15.92
50D MA
$16.65
Beta
1.17
Avg. Volume
416,197.58
EPS (Annual)
-$1.02
P/B
0.91
Rev/Employee
$392,384.61
$10,971.61
Loading...
Loading...
News
all
press releases
Bausch + Lomb (NYSE:BLCO) Issues Earnings Results
Bausch + Lomb (NYSE:BLCO - Get Free Report) released its earnings results on Wednesday. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. The company had...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
AI could take 'years' off the drug development process, says Bausch + Lomb CEO Brent Saunders
AI could take 'years' off the drug development process, says Bausch + Lomb CEO Brent Saunders...
CNBC Television-YouTube·3d ago
News Placeholder
Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·3d ago
News Placeholder
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific...
Business Wire·3d ago
News Placeholder
Bausch Health Cos Q1 Earnings Call Highlights
Bausch Health Cos (NYSE:BHC) opened 2026 with what executives described as a strong performance, driven primarily by Salix and Solta Medical, while reaffirming full-year guidance for the company...
MarketBeat·4d ago
News Placeholder
Bausch + Lomb Q1 Earnings Call Highlights
Bausch + Lomb (NYSE:BLCO) reported first-quarter 2026 results that management said show improving earnings quality and operating leverage alongside steady revenue growth, driven by strength in...
MarketBeat·4d ago
News Placeholder
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +43.37% and +3.33%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. Were doing exactly what we said we would: driving sustainable growth and margin expansion, improving how...
Business Wire·4d ago
News Placeholder
Bausch + Lomb Corporation (NYSE:BLCO) Given Consensus Rating of "Hold" by Analysts
Shares of Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) have received an average rating of "Hold" from the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have issued a hold ra...
MarketBeat·9d ago
News Placeholder
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmology and Therapy published a...
Business Wire·10d ago
<
1
2
...
>

Latest BLCO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.